论文部分内容阅读
目的:探讨卵巢癌术后重组人血管内皮抑制素(恩度)腹腔灌注联合TC方案静脉化疗的近期疗效、毒副反应及生存率。方法:将我院2010年3月至2012年1月收治的86例卵巢癌术后患者,随机单盲分成观察组45例(恩度腹腔灌注联合TC静脉化疗),对照组41例(单纯TC静脉化疗),比较两组近期疗效、毒副反应及生存率。结果:观察组治疗卵巢癌近期缓解率48.9%(22/45)优于对照组26.8%(11/41),两组比较差异有统计学意义(P<0.05);两组毒副反应比较差异无统计学意义(P>0.05)。观察组3年和5年生存率分别为71.1%(32/45)和53.3%(24/45),高于对照组48.8%(20/41)和29.3%(12/41)。两组比较差异有统计学意义(P<0.05)。结论:恩度腹腔灌注联合TC方案静脉化疗可显著提高卵巢癌患者的疗效,改善生存率且不增加毒副作用。
Objective: To investigate the short-term curative effect, side effects and survival rate of patients with ovarian cancer treated with recombinant human endostatin (Endostar) peritoneal perfusion combined with TC regimen. Methods: A total of 86 patients with ovarian cancer who were treated in our hospital from March 2010 to January 2012 were randomly divided into observation group (n = 100) and control group (n = 41) Intravenous chemotherapy), compared the two groups of short-term efficacy, toxicity and survival rate. Results: The response rate of 48.9% (22/45) in observation group was better than that in control group (26.8%, 11/41), the difference was statistically significant (P <0.05) No statistical significance (P> 0.05). The 3-year and 5-year survival rates in observation group were 71.1% (32/45) and 53.3% (24/45) respectively, which were higher than those in control group (48.8%, 20/41) and 29.3% (12/41). The difference between the two groups was statistically significant (P <0.05). Conclusions: Endostar perfusion combined with TC chemotherapy can significantly improve the efficacy of ovarian cancer patients and improve the survival rate without increasing the side effects.